Israeli Company SpliSense gets Fda approval for cystic fibrosis treatment

Israeli biopharmaceutical company, SpliSense, announced that the US Food and Medicine Administration (FDA) and the European Medicines Agency have designated the cystic fibrosis treatment technology as an “orphan drug” (EMA). The FDA and EMA designate medicines and biologic technologies as orphan drugs when they are intended to treat rare diseases. “The orphan designations we received […]

Continue Reading